Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data.

Lipsitch M, Li LM, Patterson S, Trammel J, Juergens C, Gruber WC, Scott DA, Dagan R.

Vaccine. 2018 Jan 25;36(4):473-478. doi: 10.1016/j.vaccine.2017.12.015. Epub 2017 Dec 14.

2.

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.

Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.

Clin Infect Dis. 2013 Oct;57(7):952-62. doi: 10.1093/cid/cit428. Epub 2013 Jun 26.

PMID:
23804191
3.

No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.

Licciardi PV, Toh ZQ, Clutterbuck EA, Balloch A, Marimla RA, Tikkanen L, Lamb KE, Bright KJ, Rabuatoka U, Tikoduadua L, Boelsen LK, Dunne EM, Satzke C, Cheung YB, Pollard AJ, Russell FM, Mulholland EK.

J Allergy Clin Immunol. 2016 Jun;137(6):1772-1779.e11. doi: 10.1016/j.jaci.2015.12.1303. Epub 2016 Jan 26.

4.

Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.

Ojal J, Hammitt LL, Gaitho J, Scott JAG, Goldblatt D.

Vaccine. 2017 Aug 16;35(35 Pt B):4652-4657. doi: 10.1016/j.vaccine.2017.05.088. Epub 2017 Jul 21.

5.

Streptococcus pneumoniae serotype 19A: worldwide epidemiology.

Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L.

Expert Rev Vaccines. 2017 Oct;16(10):1007-1027. doi: 10.1080/14760584.2017.1362339. Epub 2017 Aug 28. Review.

PMID:
28783380
6.

Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.

Juergens C, Patterson S, Trammel J, Greenberg D, Givon-Lavi N, Cooper D, Gurtman A, Gruber WC, Scott DA, Dagan R.

Clin Vaccine Immunol. 2014 Sep;21(9):1277-81. doi: 10.1128/CVI.00172-14. Epub 2014 Jul 2.

7.

The rise and fall of pneumococcal serotypes carried in the PCV era.

Devine VT, Cleary DW, Jefferies JM, Anderson R, Morris DE, Tuck AC, Gladstone RA, O'Doherty G, Kuruparan P, Bentley SD, Faust SN, Clarke SC.

Vaccine. 2017 Mar 1;35(9):1293-1298. doi: 10.1016/j.vaccine.2017.01.035. Epub 2017 Feb 1.

PMID:
28161425
8.

Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.

Rivera-Olivero IA, Del Nogal B, Fuentes M, Cortez R, Bogaert D, Hermans PW, Waard JH.

Vaccine. 2014 Jun 30;32(31):4006-11. doi: 10.1016/j.vaccine.2014.04.027. Epub 2014 May 14.

PMID:
24837505
9.

Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Madhi SA, Violari A, Klugman KP, Lin G, McIntyre JA, von Gottberg A, Jean-Philippe P, Cotton MF, Adrian P; CIPRA 4 team.

Vaccine. 2011 Sep 16;29(40):6994-7001. doi: 10.1016/j.vaccine.2011.07.035. Epub 2011 Jul 23.

10.

Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.

Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Porat N, Gruber WC, Scott DA.

Vaccine. 2016 Aug 5;34(36):4313-20. doi: 10.1016/j.vaccine.2016.06.075. Epub 2016 Jul 12.

PMID:
27422342
11.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group.

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.

PMID:
21960186
12.

Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.

Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.

Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21.

PMID:
27986682
13.

Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.

Millar EV, O'Brien KL, Bronsdon MA, Madore D, Hackell JG, Reid R, Santosham M.

Clin Infect Dis. 2007 May 1;44(9):1173-9. Epub 2007 Mar 23.

PMID:
17407035
14.

Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.

Gladstone RA, Jefferies JM, Tocheva AS, Beard KR, Garley D, Chong WW, Bentley SD, Faust SN, Clarke SC.

Vaccine. 2015 Apr 21;33(17):2015-21. doi: 10.1016/j.vaccine.2015.03.012. Epub 2015 Mar 14.

15.

Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.

Akinsola AK, Ota MO, Enwere GC, Okoko BJ, Zaman SM, Saaka M, Nsekpong ED, Odutola AA, Greenwood BM, Cutts FT, Adegbola RA.

PLoS One. 2012;7(2):e31050. doi: 10.1371/journal.pone.0031050. Epub 2012 Feb 20.

16.

Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.

Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.

J Infect Dis. 2015 Apr 1;211(7):1144-53. doi: 10.1093/infdis/jiu576. Epub 2014 Oct 29.

PMID:
25355940
17.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.

18.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.

Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2015 Mar 30;33(14):1719-25. doi: 10.1016/j.vaccine.2015.02.005. Epub 2015 Feb 17.

PMID:
25698485
19.

Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.

Ben-Shimol S, Givon-Lavi N, Greenberg D, Dagan R.

Hum Vaccin Immunother. 2016;12(2):268-76. doi: 10.1080/21645515.2015.1095414.

20.

The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.

Dagan R, Givon-Lavi N, Porat N, Greenberg D.

Vaccine. 2012 Jul 20;30(34):5132-40. doi: 10.1016/j.vaccine.2012.05.059. Epub 2012 Jun 6.

PMID:
22683519

Supplemental Content

Support Center